Literature DB >> 1380099

Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.

M Thali1, C Furman, D D Ho, J Robinson, S Tilley, A Pinter, J Sodroski.   

Abstract

Monoclonal antibodies have been isolated from human immunodeficiency virus type 1 (HIV-1)-infected patients that recognize discontinuous epitopes on the gp120 envelope glycoprotein, that block gp120 interaction with the CD4 receptor, and that neutralize a variety of HIV-1 isolates. Using a panel of HIV-1 gp120 mutants, we identified amino acids important for precipitation of the gp120 glycoprotein by three different monoclonal antibodies with these properties. These amino acids are located within seven discontinuous, conserved regions of the gp120 glycoprotein, four of which overlap those regions previously shown to be important for CD4 recognition. The pattern of sensitivity to amino acid change in these seven regions differed for each antibody and also differed from that of the CD4 glycoprotein. These results indicate that the CD4 receptor and this group of broadly neutralizing antibodies recognize distinct but overlapping gp120 determinants.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380099      PMCID: PMC289129     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

Authors:  C Y Kang; P Nara; S Chamat; V Caralli; T Ryskamp; N Haigwood; R Newman; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

2.  Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120.

Authors:  L Akerblom; J Hinkula; P A Broliden; B Mäkitalo; T Fridberger; J Rosen; M Villacres-Eriksson; B Morein; B Wahren
Journal:  AIDS       Date:  1990-10       Impact factor: 4.177

3.  A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity.

Authors:  S A Tilley; W J Honnen; M E Racho; M Hilgartner; A Pinter
Journal:  Res Virol       Date:  1991 Jul-Aug

4.  Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.

Authors:  N L Haigwood; P L Nara; E Brooks; G A Van Nest; G Ott; K W Higgins; N Dunlop; C J Scandella; J W Eichberg; K S Steimer
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

Authors:  P W Berman; T J Gregory; L Riddle; G R Nakamura; M A Champe; J P Porter; F M Wurm; R D Hershberg; E K Cobb; J W Eichberg
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

6.  Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants.

Authors:  E Helseth; M Kowalski; D Gabuzda; U Olshevsky; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

7.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.

Authors:  M Thali; U Olshevsky; C Furman; D Gabuzda; M Posner; J Sodroski
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

8.  pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane.

Authors:  B S Stein; S D Gowda; J D Lifson; R C Penhallow; K G Bensch; E G Engleman
Journal:  Cell       Date:  1987-06-05       Impact factor: 41.582

9.  Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees.

Authors:  E A Emini; P L Nara; W A Schleif; J A Lewis; J P Davide; D R Lee; J Kessler; S Conley; S Matsushita; S D Putney
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

10.  A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  T Ohno; M Terada; Y Yoneda; K W Shea; R F Chambers; D M Stroka; M Nakamura; D W Kufe
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

View more
  110 in total

1.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Reevaluation of amino acid variability of the human immunodeficiency virus type 1 gp120 envelope glycoprotein and prediction of new discontinuous epitopes.

Authors:  Y Yamaguchi-Kabata; T Gojobori
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5.

Authors:  Aarti Raja; Miro Venturi; Peter Kwong; Joseph Sodroski
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody.

Authors:  S Lee; K Peden; D S Dimitrov; C C Broder; J Manischewitz; G Denisova; J M Gershoni; H Golding
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

7.  Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Authors:  Shi-Hua Xiang; Peter D Kwong; Rishi Gupta; Carlo D Rizzuto; David J Casper; Richard Wyatt; Liping Wang; Wayne A Hendrickson; Michael L Doyle; Joseph Sodroski
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

10.  Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites.

Authors:  A Pinter; W J Honnen; S A Tilley
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.